Navigation Links
New Guidelines Seek to Streamline Care for Worst Heart Attacks
Date:12/17/2012

MONDAY, Dec. 17 (HealthDay News) -- Streamlined guidelines meant to improve treatment of patients with the most severe form of heart attack were released Monday by the American Heart Association and the American College of Cardiology.

The updated recommendations are for a type of heart attack called ST-elevation myocardial infarction (STEMI). It occurs when a cholesterol plaque ruptures and a blood clot forms within an artery leading to the heart muscle, completely blocking the blood flow. This can lead to damage to a large area of the heart.

This type of heart attack strikes about 250,000 Americans a year.

"Time is of the essence in the evaluation and treatment of these patients," Dr. Patrick O'Gara, chairman of the guidelines-writing committee, said in an American Heart Association news release. "The sooner blood flow is restored, the better the chances for survival with intact heart function."

Percutaneous coronary intervention is the preferred treatment when it can be done quickly. The treatment includes balloon angioplasty to open a clogged artery, followed by the insertion of stents to keep the artery open.

Patients who are taken to a hospital where percutaneous coronary intervention is not available should be given clot-busting drugs, if safe, followed by transfer to a facility where the angioplasty-stent treatment can be performed if needed, according to the guidelines published online Dec. 17 in the journal Circulation and the Journal of the American College of Cardiology.

The guidelines noted that patient delay in reporting symptoms is a major obstacle to timely and successful care of STEMI, and called for efforts to improve patient recognition of heart attack symptoms and to make people understand the importance of immediately calling 911 rather than traveling to the hospital by car, for example.

Among the other recommendations:

  • Emergency medical technicians
    '/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
2. Diabetes Groups Issue New Guidelines on Blood Sugar
3. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
4. New guidelines deliver concise messages for implementing cardiovascular prevention
5. New Guidelines Issued for Severe Lupus
6. U.S. Task Force Issues Blood Pressure Guidelines
7. British experts update addiction treatment guidelines
8. New prostate cancer screening guidelines face a tough sell, study suggests
9. The REMARK checklist explained: How to use guidelines on reporting tumor marker prognostic studies
10. Mayo Clinic, youth mental health experts, publish new guidelines to treat childhood aggression
11. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Guidelines Seek to Streamline Care for Worst Heart Attacks
(Date:7/24/2014)... can be reduced by enabling patients to see the ... This is just one of several recommendations made in ... University of Bristol. , Called ,Primary care factors and ... report has been compiled by researchers from the University,s ... from studies around the world. They found that patients ...
(Date:7/24/2014)... to nicotine, known as neonicotinoids, were found commonly ... new USGS study. This is the first broad-scale ... States and one of the first conducted within ... broad range of insect pests, use of neonicotinoid ... across the United States, particularly in the Midwest. ...
(Date:7/24/2014)... Becker's Hospital Review has published the 2014 ... With Great Oncology Programs." Organizations on this year's list ... care, cancer outcomes and research. , The Becker's Hospital ... rankings and awards they have received from a variety ... part of the criteria for inclusion on the list: ...
(Date:7/24/2014)... 24, 2014 The European Omega 3 & ... & structured lipids market in Europe with analysis and forecast ... $670.37 million in 2012 to $989.91 million by 2018, at ... through the TOC of the European omega 3 & structured ... analysis provided. This also provides a glimpse of the segmentation ...
(Date:7/24/2014)... July 24, 2014 The European air and ... in 2014, and is expected to register a CAGR of ... Germany, Russia, and turkey are the major spenders in the ... medium extended air defense program and multinational (MEADS) program, which ... Browse through the TOC of the Europe air and missile ...
Breaking Medicine News(10 mins):Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4
... Physical Activity, Weight Control, and Breast Cancer Risk , ... randomized controlled trials that test the impact of physical ... There are substantial observational data suggesting that regular physical ... a reduction in breast cancer risk: however, it is ...
... concerned workers, navigating quarantine barriers and liabilities are ... epidemic-wary managersNEW YORK, April 28 Business managers ... government advisories should prepare to handle difficult legal ... pandemic scenario, says New York litigation partner Kenneth ...
... Acetaminophen, NSAIDs can cause liver or stomach illness ... 28 (HealthDay News) -- Many over-the-counter painkillers and ... on the potential danger of liver damage and ... Manufacturers will have to include these warnings on ...
... a statement of Debra L. Ness, President National Partnership for ... able to quickly bring the swine flu outbreak under control ... But that will happen more quickly if people can follow ... are trying to contain this potential pandemic. Unfortunately, in ...
... DATATRAK International, Inc. (Nasdaq: DATA ), ... solutions for the clinical trials industry, today reported that ... the newest member of the DATATRAK CRO Connect Program(TM). ... CROs, CPI is able to expand its electronic data ...
... State today issued an alert recommending that American citizens ... due to a recent outbreak of Swine Flu. While ... evolve, InsureMyTrip.com is reminding travelers of the ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO )"Right ...
Cached Medicine News:Health News:JNCI April 28 tip sheet 2Health News:JNCI April 28 tip sheet 3Health News:JNCI April 28 tip sheet 4Health News:Swine Flu Plans Triggering Difficult Legal Questions, Says Noted Pillsbury Attorney 2Health News:Swine Flu Plans Triggering Difficult Legal Questions, Says Noted Pillsbury Attorney 3Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:Stay Home with Swine Flu Symptoms? Not Without Paid Sick Days 2Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 2Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 3Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 4Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 2Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 3Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 4Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 5Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 6
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
(Date:7/24/2014)... July 24, 2014 HIGHLIGHTS:Q2 2014 Results ... , Reported sales increased 3% to $701 million.  Sales ... rates added one percentage point to sales growth. , ... 6% in Applied and 1% in SAFC Commercial. , ... 2013, an increase of 13%.  Adjusted diluted EPS in Q2 ...
(Date:7/24/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro ® has been ... Capacity (DLCO) for phase 2 of the COPDGene ® ... Pulmonary Disease (COPD) ever undertaken.  COPD is now the ... affects millions of people worldwide.  In ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15
... and Company (NYSE: LLY ) announced that ... Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution ... study objective to restore testosterone levels to the normal ... testosterone. In addition, secondary outcomes showed that the treatment ...
... Wis., June 28, 2011 Novelos Therapeutics, Inc. ... for treatment and diagnosis of cancer, today announced that ... the defendants, motion to dismiss the putative federal securities ... Court for the District of Massachusetts in March 2010 ...
Cached Medicine Technology:Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 3Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 4Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 5Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 6Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 2Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 3
Fiber optic illumination with XHL xenon halogen illumination. Large-diameter glass viewing window with 3X magnification, airtight window seal and swivelling viewing window....
Compact format, fiber optic illumination for uniform reflection-free light. Polycarbonate housing with chrome-plated cone....
Sleek, all-metal head with large-diameter viewing window. 3X magnification....
Provides bright output and rotating lens with ultra-seal for pneumatic otoscopy....
Medicine Products: